ADAP insider transactions
Adaptimmune Therapeutics plc (ADAP) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for ADAP
- SEC Form 3 filed by new insider Hill Christopher James3 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Financial Officer Wood Gavin sold $950 worth of Ordinary Shares with a nominal value of GBP0.001 per share (96,000 units at $0.01), closing all direct ownership in the company (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Operating Officer Bertrand William C Jr sold $2,091 worth of Ordinary Shares with a nominal value of GBP0.001 per share (207,000 units at $0.01), decreasing direct ownership by 17% to 986,352 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Director Behbahani Ali sold $229,172 worth of Ordinary Shares with a nominal value of 0.001 GBP per share (19,500,000 units at $0.01) (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Large owner Ecor1 Capital, Llc sold $6,890,236 worth of Ordinary Shares (64,052,538 units at $0.11) (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Chief Operating Officer Bertrand William C Jr4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Brewer Joanna Elizabeth4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Chief Patient Supply Officer Lunger John4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Chief Commercial Officer Piccina Cintia4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Norry Elliot4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Rawcliffe Adrian4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Medical Officer Norry Elliot sold $3,243 worth of American Depositary Shares representing Ordinary Shares (5,584 units at $0.58), decreasing direct ownership by 43% to 7,510 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Patient Supply Officer Lunger John sold $3,243 worth of American Depositary Shares representing Ordinary Shares (5,584 units at $0.58), decreasing direct ownership by 43% to 7,510 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Operating Officer Bertrand William C Jr sold $3,243 worth of American Depositary Shares representing Ordinary Shares (5,584 units at $0.58), decreasing direct ownership by 43% to 7,510 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Executive Officer Rawcliffe Adrian sold $17,773 worth of American Depositary Shares representing Ordinary Shares (30,601 units at $0.58), decreasing direct ownership by 41% to 44,327 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Executive Officer Rawcliffe Adrian sold $34,639 worth of American Depositary Shares representing Ordinary Shares (59,569 units at $0.58), increasing direct ownership by 37% to 41,582 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Commercial Officer Piccina Cintia sold $7,467 worth of American Depositary Shares representing Ordinary Shares (12,991 units at $0.57), decreasing direct ownership by 41% to 18,421 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Medical Officer Norry Elliot sold $12,920 worth of American Depositary Shares representing Ordinary Shares (22,195 units at $0.58), increasing direct ownership by 36% to 13,756 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Patient Supply Officer Lunger John sold $11,360 worth of American Depositary Shares representing Ordinary Shares (19,542 units at $0.58), increasing direct ownership by 36% to 13,756 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Operating Officer Bertrand William C Jr sold $11,360 worth of American Depositary Shares representing Ordinary Shares (19,542 units at $0.58), increasing direct ownership by 36% to 13,756 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Director Behbahani Ali4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Director Mott David M4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Director Menzel Garry E4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Director Hege Kristen4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Director Hegde Priti4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Director Furey John4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Director Alleva Lawrence M4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Director Allen Andrew R4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Chief Commercial Officer Piccina Cintia sold $22,814 worth of American Depositary Shares representing Ordinary Shares (24,531 units at $0.93), decreasing direct ownership by 39% to 38,293 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- New insider Ecor1 Capital, Llc claimed ownership of 164,424,420 units of Ordinary Shares (SEC Form 3)3 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Piccina Cintia4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Rawcliffe Adrian sold $27,594 worth of American Depositary Shares representing Ordinary Shares (39,384 units at $0.70), increasing direct ownership by 92% to 44,848 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Norry Elliot sold $14,106 worth of American Depositary Shares representing Ordinary Shares (20,563 units at $0.69), increasing direct ownership by 241% to 19,257 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Lunger John sold $15,889 worth of American Depositary Shares representing Ordinary Shares (22,795 units at $0.70), increasing direct ownership by 62% to 19,015 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Bertrand William C Jr sold $16,423 worth of American Depositary Shares representing Ordinary Shares (23,589 units at $0.70), increasing direct ownership by 73% to 20,201 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Behbahani Ali4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Bertrand William C Jr4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Hege Kristen4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Lunger John4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Brewer Joanna Elizabeth4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Tayton-Martin Helen Katrina4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Wood Gavin4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Norry Elliot4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Rawcliffe Adrian4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Bertrand William C Jr sold $7,813 worth of American Depositary Shares representing Ordinary Shares (9,229 units at $0.85), decreasing direct ownership by 22% to 7,874 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Norry Elliot sold $10,015 worth of American Depositary Shares representing Ordinary Shares (11,808 units at $0.85), increasing direct ownership by 17% to 11,841 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Rawcliffe Adrian sold $24,734 worth of American Depositary Shares representing Ordinary Shares (29,202 units at $0.85), decreasing direct ownership by 13% to 26,388 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- Lunger John sold $7,813 worth of American Depositary Shares representing Ordinary Shares (9,229 units at $0.85), decreasing direct ownership by 22% to 7,874 units (SEC Form 4)4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 3 filed by new insider Hege Kristen3 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4: Rawcliffe Adrian sold $1,874 worth of American Depositary Shares representing Ordinary Shares (2,403 units at $0.78), decreasing direct ownership by 41% to 3,449 units4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4: Lunger John sold $2,804 worth of American Depositary Shares representing Ordinary Shares (3,096 units at $0.91), decreasing direct ownership by 40% to 4,718 units4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Menzel Garry E4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Hegde Priti4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Allen Andrew R4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Menzel Garry E4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Behbahani Ali4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Hegde Priti4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Furey John4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Menzel Garry E4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
- SEC Form 4 filed by Sigal Charles Elliott4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)